|1.||Matsumoto, Yoh: 5 articles (11/2006 - 05/2002)|
|2.||Stamatopoulos, Kostas: 4 articles (01/2013 - 01/2007)|
|3.||Mozes, E: 4 articles (09/2004 - 02/2000)|
|4.||Polonelli, Luciano: 3 articles (01/2015 - 01/2010)|
|5.||Travassos, Luiz R: 3 articles (01/2015 - 01/2010)|
|6.||Luider, Theo M: 3 articles (12/2013 - 01/2011)|
|7.||Rosenquist, Richard: 3 articles (12/2010 - 02/2004)|
|8.||Jee, Youngheun: 3 articles (10/2004 - 05/2002)|
|9.||Zinger, H: 3 articles (09/2004 - 02/2000)|
|10.||Yu, Wei: 2 articles (12/2015 - 06/2008)|
04/01/1995 - "By using third-complementarity-determining region (CDRIII)-specific probes, minimal residual disease (MRD) was detected in remission marrow, collected 1 month before ABMT. "
02/01/2008 - "Tissues from the surgical margins of the resected stomach were analyzed by polymerase chain reaction-based amplification of the complementarity-determining region 3 of the IgH gene for the presence of residual tumors. "
11/01/1997 - "The uniqueness of the complementarity determining region III (CDRIII) has been utilized successfully in the last decade for development of a patient specific, molecular, polymerase chain reaction (PCR)-based assay for determining minimal residual disease in various lymphoid malignancies. "
07/15/1993 - "Sequence analysis of VHDJH rearrangements at diagnosis may therefore allow a prediction of the reliability of complementarity determining region 3 probes for the detection of minimal residual disease."
08/01/1997 - "Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma."
01/01/1998 - "Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice."
08/01/2014 - "To explore the dominant complementarity-determining regions 3 (CDR3) of CD8(+) T cell populations induced by the infection of this parasite, sequence analysis was performed in this study for CDR3 of CD8(+) T cells from E. "
12/01/2001 - "To study the modifications of the T cell repertoire during an acute viral infection in rainbow trout, we adapted the immunoscope methodology, which consists of spectratyping the complementarity-determining region 3 length of the TCRbeta chain. "
12/15/2007 - "T cell receptor gene analyses of 2 unrelated DRB1*0101-positive patients with HAM/TSP showed similar Vbeta repertoires and amino acid motifs in complementarity-determining region 3. Our data suggest that efficient clonal expansion of virus-specific CD4(+) T cells in patients with HAM/TSP does not simply reflect higher viral burden but rather reflects a rapid turnover caused by preferential infection and/or in vivo stimulation by major histocompatibility complex-peptide complexes."
12/01/2001 - "Using viral hemorrhagic septicemia virus (VHSV), which provokes an acute infection in rainbow trout, we identified skewed complementarity-determining region 3 size profiles for several VbetaJbeta combinations, corresponding to T cell clonal expansions during primary and secondary response to VHSV. "
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
08/16/1990 - "Using a sensitive new method--identifying complementarity-determining region III sequences with the polymerase chain reaction--we estimated the number of residual leukemic cells in the bone marrow of eight children with B-lineage lymphoblastic leukemia before and after remission. "
04/01/1994 - "To determine whether the ALL (acute lymphoblastic leukemia) CDR3 (third complementarity-determining region) repertoire represents the recombination repertoire, or shows evidence of selectional processes inherent to normal B cell differentiation or malignant transformation, we analyzed 68 ALL CDR3 regions and included 127 previously published sequences in the analyses. "
04/01/1994 - "B precursor acute lymphoblastic leukemia third complementarity-determining regions predominantly represent an unbiased recombination repertoire: leukemic transformation frequently occurs in fetal life."
08/01/1993 - "In B-precursor acute lymphoblastic leukemia (ALL), the nucleotide sequence of the complementarity determining region III (CDRIII) in the rearranged immunoglobulin heavy chain gene (IgH) has been used as a molecular fingerprint to identify the leukemic cells. "
11/15/1990 - "Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes."
12/01/2013 - "TCRγ9δ2(OT3) is a tumor-specific TCR with an unique complementarity-determining region 3 (CDR3) sequence, referred to as OT3, in its δ2 chain. "
07/15/2010 - "These findings show that a short peptide that binds specifically to the complementarity-determining regions of the A20 BCR allows in vivo detection of neoplastic cells together with significant inhibition of tumor growth in vivo."
12/01/2008 - "Clonal amplifications, identified as repetitive TCR-beta V-region, complementarity determining region 3 (CDR3), and J-region gene sequences, were demonstrated at all sites studied, that is, peripheral blood, LNs, and metastatic tumors. "
08/01/2007 - "Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting."
04/15/2004 - "Introduction of the TCRs into proper recipient cells should reveal whether the different complementarity-determining region 3 alpha loops are important for tumor cell recognition."
|5.||Sezary Syndrome (Sezary Erythroderma)
08/01/2010 - "In this study, we analyzed the complexity of the peripheral blood T cell repertoire with a sensitive b-variable (BV) complementarity-determining region 3 (CDR3) spectratyping analysis and flow cytometry in three-stage IV CTCL/Sezary syndrome patients who achieved complete clinical remission after therapy. "
|2.||Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)
|3.||Immunoglobulin G (IgG)
|4.||DNA (Deoxyribonucleic Acid)
|7.||Immunoglobulin E (IgE)
|8.||gamma-delta T-Cell Antigen Receptors (T-Cell Receptor delta-Chain)
|2.||Drug Therapy (Chemotherapy)
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)